Propiedad y actividad de insiders de Myriad Genetics, Inc. (MYGN): operaciones de insiders, transacciones del Senado y la Cámara de EE. UU. y acciones en circulación. Sigue cómo operan la acción los directivos y los políticos.
Precio
| Precio | $3.86 |
| Capitalización | $365M |
| Bolsa | NASDAQ |
| País | US |
Operaciones Recientes de Insiders
| Fecha | Insider | Tipo | Acciones | Valor |
|---|---|---|---|---|
| 2026-09-03 | Fox Jennifer Lynne | F-InKind | 4,398 | $14K |
| 2026-08-16 | Wheeler Benjamin Richard | F-InKind | 8,761 | $27K |
| 2026-06-23 | Skovronsky Daniel | |||
| 2026-06-11 | Raha Samraat S. | A-Award | 3,542 | $14K |
| 2026-06-11 | Donnelly Brian J | A-Award | 5,000 | $20K |
| 2026-06-08 | Kumar Rashmi | S-Sale | 15,000 | $67K |
| 2026-06-04 | Skovronsky Daniel | A-Award | 59,701 | |
| 2026-06-04 | Newcomer Lee Nisley | A-Award | 59,701 | |
| 2026-06-04 | Davis Mark Steven | A-Award | 59,701 | |
| 2026-06-04 | Phanstiel S. Louise | A-Award | 59,701 |
Balance (10 años)
| Año | 2017 | 2018 | 2019 | 2020 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Caja y Equivalentes | $102.4M | $110.9M | $93.2M | $163.7M | $117.0M | $257.4M | $56.9M | $132.1M | $102.4M | $149.6M |
| Inversiones a Corto | $48.3M | $69.7M | $43.7M | $54.1M | $33.7M | $81.4M | $58.0M | $8.8M | 0 | 0 |
| Cuentas por Cobrar | $95.9M | $103.3M | $138.6M | $71.0M | $89.5M | $91.3M | $101.6M | $114.3M | $121.2M | $115.3M |
| Inventario | $42.2M | $34.3M | $31.4M | $29.1M | $27.1M | $15.3M | $20.1M | $22.0M | $27.5M | $30.6M |
| Activos Corrientes | $301.7M | $327.6M | $348.6M | $331.7M | $389.4M | $484.8M | $274.6M | $313.6M | $298.0M | $332.6M |
| Inmovilizado Material | $51.1M | $43.2M | $57.3M | $103.0M | $100.4M | $125.3M | $187.3M | $180.6M | $172.4M | $163.4M |
| Fondo de Comercio | $316.1M | $318.6M | $417.2M | $327.6M | $329.2M | $239.2M | $286.8M | $287.4M | $286.3M | $51.6M |
| Activos Intangibles | $491.5M | $455.2M | $684.7M | $605.3M | $578.8M | $404.1M | $379.7M | $349.5M | $262.4M | $153.4M |
| Activos Totales | $1.21B | $1.18B | $1.56B | $1.40B | $1.42B | $1.32B | $1.20B | $1.15B | $1.03B | $706.6M |
| Cuentas por Pagar | $22.0M | $26.0M | $33.3M | $21.7M | $20.5M | $29.6M | $28.8M | $25.8M | $32.3M | $30.0M |
| Deuda a Corto | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pasivos Corrientes | $217.5M | $102.2M | $117.8M | $147.0M | $145.9M | $204.3M | $137.2M | $155.9M | $164.1M | $133.8M |
| Deuda a Largo | $99.1M | $9.3M | $233.5M | $224.4M | $224.8M | 0 | 0 | $38.5M | $39.6M | $119.9M |
| Pasivos Totales | $440.9M | $209.2M | $473.8M | $486.4M | $537.8M | $352.9M | $312.9M | $363.3M | $326.5M | $338.6M |
| Reservas | -$78.2M | $54.1M | $25.6M | -$173.9M | -$227.0M | -$254.2M | -$366.2M | -$629.5M | -$756.8M | -$1.12B |
| Patrimonio Neto | $768.4M | $966.1M | $1.09B | $918.2M | $881.0M | $967.8M | $885.8M | $783.2M | $701.1M | $368.0M |
| Deuda Total | $99.1M | $9.3M | $233.5M | $294.8M | $289.0M | $92.3M | $145.0M | $152.1M | $140.3M | $209.8M |
| Deuda Neta | -$51.6M | -$171.3M | $96.6M | $77.0M | $138.3M | -$246.5M | $30.1M | $11.2M | $37.9M | $60.2M |
| Capital Circulante | $84.2M | $225.4M | $230.8M | $184.7M | $243.5M | $280.5M | $137.4M | $157.7M | $133.9M | $198.8M |
Salud financiera
| Deuda / Patrimonio | 0.69 |
| Ratio corriente | 2.21 |
Rentabilidad
| Rentabilidad sobre capital | -32.59% |
| Rentabilidad sobre capital invertido | -19.13% |
| Rentabilidad sobre activos | -17.62% |
| Margen bruto | 68.83% |
| Margen operativo | -12.22% |
| Margen neto | -13.96% |
Empresas relacionadas: AMN · CDNA · CSTL · DNA · DRIO · EVH · FLGT
Explorar sector: Healthcare · Medical - Diagnostics & Research
Más secciones de MYGN: Resumen · Financieros · Valoración · Estadísticas · Estimaciones · Técnico · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones